Publications by authors named "Tzippi Shalem"
Article Synopsis
- A survey of Israeli gastroenterologists revealed that 62% prescribed biosimilar drugs in the past year, mostly to patients who were new to biologics.
- Most gastroenterologists (75%) believe that biosimilars have the same effectiveness as brand-name drugs but show resistance to switching patients, especially those in remission for over two years and pregnant women.
- Overall, while there is a general confidence in biosimilars' safety and efficacy, many physicians prefer to prescribe brand-name medications like adalimumab.
Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
Anat Yerushalmy-Feler Gemma Pujol-Muncunill Javier Martin-de-Carpi Kaija-Leena Kolho Arie Levine Tzippi Shalem
J Pediatr Gastroenterol Nutr
December 2022
Objectives: Escalation of the ustekinumab (UST) maintenance dosage was effective in adults with Crohn disease (CD), but no data are available for children. We evaluated the effectiveness and safety of dose escalation of UST in pediatric CD.
Methods: This was a retrospective multicenter study from 25 centers affiliated with the IBD Interest and Porto groups of ESPGHAN.